title: Revealing tumor immunity after hematopoietic stem cell transplantation.
abstract: Allogeneic hematopoietic stem cell transplantation is currently the most effective method for inducing tumor immunity. However, the diversity of target antigens recognized by donor T cells has not been established. New studies show that tumor-reactive T cells are directed against diverse tumor-specific targets as well as minor histocompatibility antigens.
authors: Cancer Vaccine Center, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
authors: Catherine J
authors: CJ
authors: Wu
authors: Jerome
authors: J
authors: Ritz
mesh_terms: D000818:Animals; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000276:immunology* / Q000601:surgery*; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology; D018448:Models, Immunological; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D014184:Transplantation, Homologous; D016896:Treatment Outcome